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INTRODUCTION AND EXPERIMENTAL 
Despite of tremendous innovations in drug delivery, the 
oral route remains the preferred route for administration of 
therapeutic agents because of accurate dosage, low cost 
therapy, self medication, non invasive method and ease of 
administration leading to high level of patient compliance. 
Pediatric patients may suffer from ingestion problems as a 
result of underdeveloped muscular and nervous control. 
Moreover, patients traveling with little or no access to 
water, limit utility of orally administered conventional 
tablets or capsules. 
Therefore, to cater the needs of such patients, recent 
advancements in technology have resulted in development 
of viable dosage alternatives popularly known as orally 
disintegrating tablets (ODTs)[1,2].During the past decade, 
the FDT (fast dissolving tablet) technology, which makes 
tablets dissolve or disintegrate in the mouth without 
additional water intake, has drawn a great deal of 
attention.The technology is also referred to as fast 
disintegrating tablet, fast dispersing tablet, rapid dissolve 
tablet, rapid melt tablet, quick disintegrating tablet, and 
orally disintegrating tablet. The FDT formulation is 
defined by the Food and Drug Administration (FDA) as ‘‘a 
solid dosage form containing medicinal substances 
which disintegrates rapidly, usually within a matter of 
seconds, when placed upon the tongue’’.The tablets 
disintegrate into smaller granules or melt inthe mouth from 
a hard solid structure to a gel like structure, allowing easy 
swallowing by the patients. The disintegration time for 
those tablets varies from a few seconds to more than a 
minute [2,3]. 
Levocetrizine dihydrochloride is the active R (-) 
enantiomer of cetrizine.It is an orally active and selective 
H1 receptor antagonist used medically as an antiallergic. It 
is bitter in taste. Taste masking is an essential requirement 
for mouth dissolving tablets for commercial success.Taste 
masking is achieved by using ion exchange resin by 
making drug: resin comlex in different ratio. In the present 
work attempt was made to use ion exchange resins as taste 
masking agents. Combinations of two superdisintegrants 
were used in the formulation of mouth dissolving tablet of 
Levocetrizine dihydrochloride. The purpose was to 
enhance patient compliance and provide fast onset of 
action.  
Materials and Methods 
Levocetrizine dihydrochloride was obtained from 
Karunesh Remedies Ltd, Anklehwar, Gujrat.  Sodium 
starch glycolate, cross carmellose sodium, crospovidone 
were obtained from Vijlak Pharma Ltd, Hyderabad. 
 
Preparation of Drug-Resin Complex: 
 First of all distilled water was added in beaker and 
then added slowly Kyron T-134 added under 
continous stirring into the vortex taking precaution to 
avoid lump formation  and allowed it to swell for 2 
hour. 
 Levocetrizine Dihydrochloride was added slowly 
under continous stirring to above resin solution. 
 Stirring was continued for 3 hours and allow it for 24 
hours. 
 The solution was filtered by using whatmann filter 
paper no 41.Residue/slurry was taken out and put it 
for drying at 60OC for 3-4 hours in oven. 
 The dry powder is the Drug –Resin complex (DRC). 
 
Preparation of Drug Granules: 
 Granules of drug-resinate earlier obtained were mixed/ 
blended with superdisintegrants (both Sodium Starch 
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Glycolate, Croscarmellose Sodium),microcrytalline 
cellulose is used as diluent, mannitol is used as mouth 
feel enhancer, aspartame as sweetner, orange dry as 
flavouring agent, talc as glidantand magnesium sterate 
as lubricant. All ingredients were pass through mesh # 
60 .Before compression hardness was adjusted. Drug-
resinate equivalent to 5mg of Levocetrizine 
dihydrochloride were compressed into tablets using 
8mm Flat Face Punch set using a 23 station tablet 
press (RIMEK INDIA). 
  
 
Table no.1 Formulation composition of batc F1 to F5 
 
                
EVALUATION OF POWDER BLEND: 
The prepared blend is evaluated by following tests. 
 Angle of repose 
 Bulk density 
 Tapped density 
 Hauser’s ratio 
 Carr’s index 
 
Angle of repose: 
Angle of repose was determined by using fixed funnel 
method. The fixed funnel method employ a funnel that was 
secured with its tip at a given height (2cm), above the 
graph paper that was placed on a flat horizontal surface. 
Granules or tablet blend were carefully poured through the 
funnel until the apex of the conical pile just touches the tip 
of the funnel. Thus, with r being the radius of the base of 
the conical pile. Angle of repose was calculated using the 
following equation. 
θ = tan-1 ( 
𝐡
𝐫
 ) 
Here h = Height of pile 
r = Radius of pile 
θ = Angle of repose 
Bulk density: 
Bulk density was determined by pouring a weighed 
quantity of tablet blend into graduated cylinder and 
measuring the height. Bulk density is the ratio of mass of 
tablet blend to bulk volume. 
𝐁𝐮𝐥𝐤 𝐃𝐞𝐧𝐬𝐢𝐭𝐲 =  
𝐦
𝐯
=  
𝐦
𝛑𝐫𝟐𝐡
 
Here; m = weight of powder or granules (gm.) 
v = Bulk Volume (cm.3) 
π = 22/7 = 3.14 
r = Radius of Cylinder (cm.) 
h = Height reached by powder in cylinder (cm.) 
Tapped Density: 
Tapped density is ratio of mass of tablet blend to tapped 
volume of tablet blend. Accurately weighed amount of 
tablet blend poured in graduated cylinder and height is 
measured. Then cylinder was allowed to 100tap under its 
own weight onto a hard surface. The tapping was 
continued until no further change in height was noted. 
𝐓𝐚𝐩𝐩𝐞𝐝 𝐃𝐞𝐧𝐬𝐢𝐭𝐲 =  
𝐦
𝐯
=  
𝐦
𝛑𝐫𝟐𝐡
 
Here; m = weight of powder or granules (gm.) 
v = Tapped Volume (cm.3) 
π = 22/7 = 3.14 
r = Radius of Cylinder (cm.) 
h = Height reached by powder in cylinder after tapping 
(cm.) 
Hausner’s Ratio: 
Hausner’s ratio indicates the flow properties of powder 
and measured by the ratio of tapped density to bulk 
density. Hausner’s ratio was determined by the given 
formula 
𝐇𝐚𝐮𝐬𝐧𝐞𝐫’𝐬 𝐫𝐚𝐭𝐢𝐨 =  
𝐓𝐚𝐩𝐩𝐞𝐝 𝐝𝐞𝐧𝐬𝐢𝐭𝐲
𝐁𝐮𝐥𝐤 𝐝𝐞𝐧𝐬𝐢𝐭𝐲
 
Carr’s Index (Compressibility Index): 
Compressibility is the ability of powder to decrease in 
volume under pressure using bulk density and tapped 
Name of Ingrdients Formulation code Quantity (in mg) 
F1 F2 F3 F4 F5 
Levocetrizine Dihydrochloride 5 5 5 5 5 
Kyron T-134 15 15 15 15 15 
Crosscarmellose Sodium 2.5 3 3.5 4 4.5 
Sodium Starch Glycolate 2 2 2 2         2 
Mannitol 73 73 73 73 73 
Magnesium Stearate 2 2 2 2 2 
Colloidal Silicon Dioxide(Aerosil 200) 1.2 1.2 1.2 1.2 1.2 
Talcum 2.5 2.5 2.5 2.5 2.5 
Aspartame 3 3 3 3 3 
Flv orange dry 0.8 0.8 0.8 0.8 0.8 
Menthol 0.05 0.05 0.05 0.05 0.05 
MCC PH (102) up to 135 135 135 135 135 
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density the percentage compressibility of powder were 
determined, which is given as carr’s compressibility index. 
It is indirectly related to the relative flow rate. Carr’s 
compressibility index was determined by the given 
formula 
𝐂𝐚𝐫𝐫′𝐬 𝐈𝐧𝐝𝐞𝐱 = (𝟏 −
𝐁𝐮𝐥𝐤 𝐃𝐞𝐧𝐬𝐢𝐭𝐲
𝐓𝐚𝐩𝐩𝐞𝐝 𝐃𝐞𝐧𝐬𝐢𝐭𝐲
 ) × 𝟏𝟎𝟎 
EVALUATION OF TABLETS 
These tests are as following:- 
 Appearance 
 Thickness 
 Hardness 
 Weight variation 
 Friability 
 Disintegration 
 Uniformity of dispersion 
 Wetting Time 
 Water absorption ratio 
 Drug content 
 In vitro Dissolution 
 Stability studies 
Appearance: 
The general appearance of tablet is its visual identity and 
all over elegance, shape, color, surface textures. These all 
parameters are essential for consumer acceptance. Tablets 
have smooth, clean surface, round concave shaped, white 
color tablet with pleasant taste. 
Thickness: 
The thickness of the tablets was determined by using 
vernier calipers. Randomly 10 tablets selected were used 
for determination of thickness that expressed in Mean± SD 
and unit is mm. 
Hardness: 
The hardness of tablet is an indication of its strength 
against resistance of tablets to capping, abrasion or 
breakage under conditions of storage, transportation and 
handling before usage. Measuring the force required to 
break the tablet across tests it. Hardness of 10 tablets 
(randomly) from whole tablet batch was determined by 
Monsanto hardness tester. Hardness measured in kg/cm2. 
Weight variation: 
The weight variation test is carried out in order to ensure 
uniformity in the weight of tablets in a batch. The total 
weight of 20 tablets randomly from whole batch was 
determined and the average was calculated. The individual 
weights of the tablets were also determined accurately and 
the weight variation was calculated. 
Friability test: 
Friability is the loss of weight of tablet in the container due 
to removal of fine particles from the surface during 
transportation or handling. Roche friabilator was employed 
for finding the friability of the tablets. For tablets with an 
average weight of 0.65 g or less take a sample of whole 
tablets corresponding to about 6.5 g and for tablets with an 
average weight of more than 0.65 g take a sample of 10 
whole tablets. Roche friabilator is rotated at 25rpm for 4 
minutes for 100rounds. The tablets were dedusted and 
weighed again. The percentage of weight loss was 
calculated using the formula 
%f =
𝐖𝟎−𝐖𝟏
𝐖𝟎
 x 100 
Here, %f = Percentage friability 
W0 = Initial weight (Before test) 
W1 = Final weight (After test) 
Disintegration test: 
The USP device to rest disintegration was six glass tubes 
that are “3 long, open at the top, and held against 10” 
screen at the bottom end of the basket rack assembly. One 
tablet is placed in each tube and the basket rack is 
poisoned in 1 liter beaker of distilled water at 37± 2oC, 
such that the tablets remain below the surface of the liquid 
on their upward movement and descend not closer than 
2.5cm from the bottom of the beaker. 
Wetting Time: 
The wetting time of the tablets was measured using a 
simple procedure. Five circular tissue papers of 10cm 
diameter were placed in a petridish containing 0.2% w/v 
solution of amaranth (10ml). One tablet was carefully 
placed on the surface of the tissue paper. The time required 
for develop blue color due to amaranth water soluble dye 
on the upper surface of the tablets was noted as the wetting 
time. 
Water Absorption Ratio: 
A small piece of tissue paper folded twice was placed in a 
small petridish containing 6ml of water. A tablet was put 
on the paper. The wetted tablet was then weighed. Water 
absorption ratio, R was determined by using following 
formula 
R =
𝐖𝐚−𝐖𝐛
𝐖𝐛
 x 100 
Here,    R  =  Water absorption ratio 
Wb = Weight of tablet before water absorption 
Wa = Weight of tablet after water absorption 
Drug content: 
10 tablets were powdered and 100mg drug equivalent 
powder dissolved in suitable media 0.1N HCl. Volume of 
the solution made up to 100ml by that media. Solution was 
filtered and diluted 100times and analyzed 
spectrophotometrically and further calculation carried out 
to determine drug content in one tablet. 
In-vitro drug release studies: 
The mouth dissolving tablets are subjected to in-vitro drug 
release studies in 0.1N HCl for 30 minutes to access the 
ability of the formulation for providing immediate drug 
delivery. Drug release studies were carried out in 
dissolution test apparatus USP type II using specified 
volume 900ml of dissolution media maintained at 
37±0.5oC. The tablets are directly placed in medium with 
paddle then rotated at 50 rpm. 5ml of the sample from the 
dissolution medium are withdrawn at each time interval (1, 
2, 3, 4 ,5, 6, 7, 8, 9, 10 minutes) and 5ml of fresh medium 
was replaced each time. The samples were filtered and 
from the filtrate 1ml was taken and diluted to 10ml with 
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0.1N HCl. These samples were analyzed 
spectrophotometrically and further calculation was carried 
out to get drug release. The drug released data were plotted 
as cumulative % drug release Vs time. 
Stability study: 
Stability is defined as the ability of a particular drug or 
dosage form in a specific container to remain within its 
physical, chemical, therapeutic, and toxicological 
specifications. Drug decomposition or degradation occurs 
during storage, because of chemical alteration of the active 
ingredients or due to product instability, lowering the 
concentration of the drug in the dosage form. The stability 
study indicates that the formulation is quite stable at 
different conditions of storage. Accelerated stability 
studies carried out at 40°C ± 2°C/75% RH ± 5% RH for 3 
months. 
From the evaluation of dosage form batch F4 optimized so 
that this formulation was now processed from beginning to 
ensure reproducibility of this formulation and then stability 
study were carried out for three months on new batch 
formed of F4. Stability studies were carried out as per ICH 
stability testing guidelines (ICH guidelines). The 
optimized formulation F4 was stored in aluminium capped 
clear glass vials and were subjected to a storage condition 
of 40°C±2oC/ 75%±5% RH for 3 months in humidity 
chamber. The samples were withdrawn at time intervals of 
0, 1, 2, 3 months and evaluated for hardness, friability, 
disintegration time, drug content and in-vitro dissolution 
study. 
RESULT AND DISCUSSION: 
FLOW PROPERTIES OF GRANULES: 
Angle of Repose of Granules: 
All batches were evaluated for flow property. The results 
of all the batches were shown in table 18.
 
Table 2: Angle of repose of granules of batch F1 to F5 
Batch No.    Height of Pile (cm)   Radius (r) (cm) Tan    Angle of Repose(θ) 
F1 2.0 3.951 0.506 26.85 
F2 2.0 3.777 0.529 27.90 
F3 2.0 3.638 0.549 28.80 
F4 2.0 3.834 0.522 27.55 
F5 2.0 3.660 0.506 26.85 
 
From the results of flow properties of the all batches, it is concluded that all batches had good flow property.  
 
Table 3: Physicomechanical properties of batch F1 to F5  
Batch No. 
Mass of powder 
blend (gm) 
Initial 
 volume 
(ml) 
Bulk Density 
  (gm/cm
3
) 
After 
 Tap volume 
   (ml) 
Tapped 
Density 
 (gm/cm
3
) 
  Hausner’s 
Ratio 
(H
R
) 
Carr’s 
Index (%) 
F1    10 14.9 0.161 12.9 0.186 1.15 13.42 
F2 10 15.1 0.159 12.1 0.199 1.24 19.86 
F3 10 14.7 0.163 12.5 0.193 1.17 14.96 
F4 10 16.1 0.149 12.9 0.187 1.25 19.87 
F5 10 15.9 0.151 12.8 0.188 1.24 19.49 
 
From the results of precompression studies of the batch 
F1-F5, it is concluded that powder mixtures has good flow 
property and compressibility property. The bulk density of 
powder mixtures were found to be in the range of 0.148-
0.168 g/cm3. Bulk density of F1-F5 formulations were 
reduced to 0.168-0.148 gm/cm3, which indicates the higher 
bulk volume and thereby higher porosity of powder 
mixture which is desirable to support the rapid 
disintegration. The values of Carr’s index were in the 
range of 12.58 - 25.34 and Hausner’s ratio was in the range 
of 1.14-1.33 were suggesting fairly good flow properties.  
Post-compression parameters- 
The powder blend was compressed using direct 
compression technique. Tablets prepared by direct 
compression method have found to be good without any 
chipping, capping and sticking. Various physical 
parameters like thickness, hardness, weight variation, 
friability, hardness, disintegration time were measured to 
evaluate tablets. It is found that the average thickness of 
the tablets also ranged between2.51 -2.59 mm; however, 
the variations have not alarming and remained within the 
acceptable range.Hardness of tablets of the different 
formulations varied widely ranging from 2.3 – 2.8 kg/cm
2
 
(Table 3), all the formulations have therefore thought to 
show the acceptable hardness.  
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Table 4: Post Compression Evaluation 
Batch No. Thickness Hardness Weight Varation Friability 
F1 2.54 ±0.015 2.6 ± 0.199 134.05±2.25 0.445 
F2 2.51± 0.013 2.8 ± 0.263 133.95±2.43 0.443 
F3 2.59±.012 2.4 ± 0.648 133.5±2.32 0.296 
F4 2.54± 0.015 2.3 ± 0.288 134.1±2.25 0.444 
F5 2.52± 0.023 2.4 ± 0.733 133.9±2.29 0.259 
 
Table 5: Post Compression Evaluation 
Batch No. 
Average Disintegration 
Time (sec) 
Average Wetting 
Time (sec) 
Water absorption 
ratio(%) 
% drug content 
F1 59 ± 0.365 18 ± 0.324 76.41 ± 0.96 96.99 ± 0.928 
F2 53 ± 0.863 16 ± 0.231 78.46 ± 0.392 97.37 ± 0.586 
F3 42 ± 0.863 16± 0.621 78.34 ± 0.503 97.62 ± 1.613 
F4 36 ± 0.563 15 ± 0.503 83.17 ± 0.52 98.93 ± 0.914 
F5 29 ± 0.261 14 ± 0.365 85.23 ± 0.183 99.62± 0.381 
 
As per the pharmacopoeial requirement, formulation of 
fast disintegrating tablet exhibited disintegration time in 
≤60 seconds; F1 to F5 batches passes the disintegration 
time requirement. From the above it is observed that all the 
prepared formulations exhibited disintegration time less 
than 60 seconds from F1 to F5 batches.  F5 batch exhibited 
the least disintegration time i.e. 29 seconds. So from above 
observation it is concluded that the optimized formulations 
(batch F5) contains disintegrants in the ratio of 4.5:2 
(Croscarmellose sodium: sodium starch gycolate). Wetting 
time from F1 and F5 were 14 and 18 respectively and 
those were significantly lower due to highly porous 
structure. Due to high levels of croscaremellose sodium 
and sodium starch glycolate, there was high water uptake. 
% drug content is in the range of 96.99-99.62, also within 
the limits. 
In-vitro drug release: 
Dissolution parameter: 
Medium: 0.1 N HCl 
Volume: 900 ml 
Apparatus: USP Type II (Paddle) 
Speed: 50 rpm 
Time Point: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 minutes 
Temperature: 37oC  
Identification: At 230.1 nm in UV-Visible 
spectrophotometer
                                                     Table 6: In-vitro drug release profile of batches F1 to F5 
Time (min) 
Cumulative % drug release 
F1 F2 F3 F4 F5 
0 0 0 0 0 0 
1 23.806 20.903 22.645 21.484 24.968 
2 29.032 29.613 29.613 27.871 30.194 
3 38.323 38.903 39.484 39.484 40.065 
4 54.581 54.000 52.839 53.419 55.161 
5 62.129 63.290 63.871 59.806 63.871 
6 66.774 67.355 67.935 70.258 69.097 
7 77.806 75.484 76.645 79.387 79.548 
8 87.677 84.774 89.419 87.516 90.000 
9 90.000 91.742 91.742 93.112 93.484 
10 96.387 96.968 97.548 98.125 99.290 
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Figure 1: In-vitro drug release of batches F1 to F5 
The highest release was obtained with the optimum level 
of super disintegrates in batches F3, F4, F5 and drug 
release was found to be  97.548, 98.125 and 99.290 % 
respectively in dissolution period 10 minutes. Amongst all 
these batches F5 showed highest drug release having ratio 
of 4.5 : 2 (croscarmellose sodium: sodium starch glycolate) 
i.e. 99.290% in 10 min. Hence, batch F5 was selected as 
optimized batch.
 
STABILITY STUDIES OF OPTIMIZED BATCH: 
Table 7: Stability data for optimized formulation F5 
Formulation Parameters Evaluated 
Time interval (months) 
0 1 2 3 
F5 
Disintegration time (sec) 22 23 21 23 
Hardness (kg/cm2) 2.4 2.5 2.4 2.6 
Friability (%) 0.314 0.309 0.328 0.322 
% drug content 99.29 99.45 99.23 98.76 
 
Table 8: Dissolution profile of optimized batch F5 
Time (min) 
Cumulative % drug release 
Initial After 1 month After 2 months After 3 months 
0 0 0 0 0 
1 22.645 22.065 20.903 23.226 
2 27.290 26.129 26.129 29.613 
3 37.161 38.903 38.323 39.484 
4 54.000 55.742 51.677 56.323 
5 64.452 65.613 62.710 63.871 
6 69.097 70.258 68.516 70.839 
7 80.710 78.968 79.548 81.290 
8 89.419 91.742 88.258 87.677 
9 92.323 94.645 94.645 90.581 
10 99.290 98.710 99.290 98.129 
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Figure 2: Dissolution profile of optimized formulation F5 
The stability study revealed that all the formulations were 
physically stable when stored at 40±20 c and 75±5 % RH 
till 3 months and there was no significant difference in 
dissolution for optimized formulation. 
CONCLUSION: 
Levocetrizine dihydrochloride is the active R (-) 
enantiomer of cetrizine.It is an orally active and selective 
H1 receptor antagonist used medically as an antiallergic. 
Our aim was to prepare mouth dissolving tablets with 
quality consistent by using production friendly direct 
compression which avoids costly technology, equipment 
and lengthy manufacturing process. The process is simple 
and easy to demonstrate as observed from result batch 
manufactured. 
In the present work attempt was made to use ion exchange 
resins as taste masking agents. Combinations of two 
superdisintegrants were used in the formulation of mouth 
dissolving tablet of Levocetrizine dihydrochloride. The 
purpose was to enhance patient compliance and provide 
fast onset of action.  
Kyron T-134 was used as ion exchange resins and it was 
mixed with the drug in different ratios and evaluated for 
the extent of complexation. Results show that with Kyron 
T-134, drug to resin ratio of 1:3 gave maximum amount of 
complexation. 
These drug-resin complex exhibited satisfactory values for 
angle of repose and bulk density. Drug content estimation 
showed more than 90% of the drug present. The 
disintegration tests conducted on these products show that, 
there is faster disintegration of the tablets, taking 29 to 59 
seconds, which is much less than the official limit for fast 
disintegrating tablets (1minutes). After disintegration, the 
dispersion produced was smooth with pleasant mouth feel 
and the bitter taste was totally masked. 
The tablet's diameters and thickness is uniform and weight 
variation is very well within ±7.5% of the standard value 
in all batches. 
The measured average hardness of all the formulations met 
the in house limits. The % drug content of tablets in all 
formulations is found to be between 90-110% which 
complied with limits established in Indian Pharmacopoeia. 
The % friability is less than 1% in all the batches, ensuring 
that the tablets were mechanically stable. 
All the tablets pass the weight variation test as % weight 
variation is within the pharmacopoeial limit i.e.7.5% to be 
compliance with the Indian pharmacopeias standards. 
Optimized batch F5 show very less disintegration time (29 
sec) and the wetting times in the batch F5 is also less. 
Results of taste evaluation by panel method revealed that 
Kyron T-134 (R) mask the bitter taste of drug at 1:3 ratios. 
The data was indicating there is a highly significant 
difference between the ratings of taste, attributed to 
effective masking the bitter taste of Levocetrizine 
dihydrocloride effectively.  
In vitro drug release profile of tablets in shown 99% drug 
release in 10 minutes indicating that the drug will be 
absorbed faster in the mouth, pharynx and oesophagus and 
thus enhance the bioavailability by pregastric absorption 
through mouth, pharynx and oesophagus. 
Stability study was conducted. There is no significant 
taste, color change at significant temperature. There is no 
significant variation in the disintegration time, hardness, 
friability and in-vitro dissolution profiles at months of 
stability studies for the optimized formulation F5 at 
different temperatures. 
In conclusion, the objective of taste masking and 
formulation development & evaluation of mouth 
dissolving tablets of Levocetrizine dihydrocloride was 
achieved. The effective taste masking is achieved for 
Levocetrizine dihydrocloride by preparation of complex 
using Kyron T-134. The formulated tablets that had a good 
taste and rapidly disintegrated in the mouth are useful and 
practical for pediatric and geriatric formulation. Thus, the 
formulated tablets of Levocetrizine Dihydrochloride can 
be prepare at industry scale for production purpose.
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